Tirzepatide is a novel glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for the treatment of type 2 diabetes mellitus (as Mounjaro) and, more recently, for chronic weight management in adults with obesity or overweight with weight-related comorbidities (as Zepbound)
doi: 10.1172/JCI29881 29 SchmidtFMWeschenfelderJSanderCMinkwitzJThormannJChittkaTet al
Maintaining a healthy lifestyle is one of the best ways to care for our bodies, including regular exercise and a well-balanced diet
The escalation schedule exists for a reason
In the phase 2 NEJM trial, participants receiving the highest dose of retatrutide (12 mg) achieved a mean body weight reduction of approximately 24.2% from baseline at 48 weeks, compared with approximately 2.1% in the placebo group
When stored correctly in a refrigerator (2C to 8C), lyophilized Retatrutide can remain stable for many months